May 19, 2022
Japan’s all-important reimbursement policy panel on May 18 approved the results of cost-effectiveness assessments (CEAs) for Takeda Pharmaceutical’s kinase inhibitor Cabometyx (cabozantinib). The drug is likely to face no price cut under the scheme as its cost-effectiveness profile proved positive...read more